This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Vaginal Disease

Post Marketing Follow Up Study To Evaluate Performance Safety Quality of Menopausal Transition Women Treated With Ainara

Sponsored by Italfarmaco

About this trial

Last updated 4 years ago

Study ID

DMS/18/AINARA/03

Status

Completed

Type

Interventional

Phase

N/A

Placebo

No

Accepting

18-75 Years
45 to 70 Years
Female
Female

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 6 years ago

What is this trial about?

The objective of the present PMCF study with a 6 month follow up period is to identify potential new and unknown risks associated with longer term use of Ainara® and (considering the duration of symptoms in GSM) to collect additional data regarding efficacy of a long-term treatment with this medical device.

What are the participation requirements?

Yes

Inclusion Criteria

1. Women previously treated with Ainara® vaginal gel in the study DMS/18/AINARA/01 or DMS/18/AINARA/02.

2. Non-pregnant and in late menopausal transition (with a break in menstrual periods of at least 60 days), or post-menopausal (total cessation of menses for ≥ 1 year) women following STRAW criteria and considering the screening date of the study (DMS/18/AINARA/01 or DMS/18/AINARA/02) in which they were enrolled.

3. Women aged ≥ 45 to ≤ 70 years (considering the baseline date of the study DMS/18/AINARA/01 or DMS/18/AINARA/02 in which they were previously enrolled);

4. Body mass index (BMI) ≥ 18.5 to ≤ 36 kg/m2

5. Females of childbearing potential who agree to use only lubricated condoms or spiral as contraceptives methods, during the full duration of the study.

6. Able to communicate adequately with the Investigator and to comply with the requirements for the entire study.

7. Capable of and freely willing to provide written informed consent prior to participating in the study.

No

Exclusion Criteria

1. Malignancy (also leukemic infiltrates) within 5 years prior to Day 1 (except for treated basal cell/squamous cell carcinoma of the skin).

2. Genital bleeding.

3. Estrogen vaginal treatment during the study period (it was permitted only if terminated at least 6 months before study).

4. Systemic estrogen therapy (it was permitted only if terminated at least 6 months before study).

5. Subjects with illness, or other medical condition that, in the opinion of the investigator, would compromise participation or be likely to lead to hospitalization during the study.

6. Clinical evidence of acute infection currently requiring treatment (syphilis, herpes simplex, human papilloma virus, gonorrhea, chlamydia, lymphogranuloma venereum, etc.); clinical evidence or history of chronic infectious disease (i.e. tuberculosis).

7. Psychosis, schizophrenia, mania, depressive disorders, history of suicide attempt or suicidal ideation, or any other psychiatric illness (except for intermittent anxiety).

8. Known allergy to tested IMDs or its excipients.

9. Drug or alcohol abuse 12 months prior to Day 1.

10. Participation in an interventional clinical study or administration of any investigational agents in the previous 30 days (except DMS/18/AINARA/01 or DMS/18/AINARA/02).

11. Presence of any clinically significant medical condition judged by the investigator to preclude the patient's inclusion in the study.

Locations

Location

Status